Table 1.
Baseline patient characteristics for EULAR good/moderate responders and non-responders after 16 weeks of adalimumab treatment
| All patients (n=48) | EULAR g/m (n=38) | EULAR non (n=10) | p Value | |
|---|---|---|---|---|
| Age (years) | 50 (13) | 51 (13) | 48 (17) | 0.49 |
| Female, n (%) | 39 (81) | 30 (79) | 9 (90) | 0.43 |
| DAS28 | 5.5 (1.1) | 5.6 (1.1) | 5.0 (0.8) | 0.11 |
| Erosive disease, n (%) | 32 (67) | 24 (63) | 7 (70) | 0.84 |
| RF, n (%) | 31 (65) | 28 (74) | 5 (50) | 0.82 |
| ACPA, n (%) | 33 (69) | 27 (71) | 6 (60) | 0.50 |
| ESR (mm/h) | 20 (11–35) | 20 (11–36) | 19 (15–21) | 0.72 |
| CRP (mg/dl) | 8 (5–19) | 7 (4–20) | 9 (6–21) | 0.74 |
| Disease duration (months) | 58 (31–143) | 60 (28–143) | 58 (36–201) | 0.55 |
| MTX dose (mg/week) | 19 (6.8) | 19 (6.5) | 19 (8.3) | 0.85 |
| Concomitant oral GC, n (%) | 13 (27) | 8 (22) | 4 (40) | 0.18 |
| BMI | 27.0 (6.1) | 27.4 (6.3) | 24.4 (4.6) | 0.17 |
| Resistin (ng/ml) | 24 (18–30) | 23 (18–29) | 26 (18–46) | 0.48 |
| Adiponectin (mg/ml) | 9.6 (7.7–14.0) | 9.4 (7.4–12.7) | 9.8 (8.4–17.9) | 0.31 |
| Vaspin (ng/ml) | 0.46 (0.26–1.03) | 0.42 (0.26–0.97) | 0.65 (0.26–1.34) | 0.51 |
| Visfatin (ng/ml) | 2.6 (1.5–3.3) | 2.5 (1.8–3.3) | 2.6 (1.0–3.2) | 0.49 |
| Leptin (ng/ml) | 57 (31–86) | 57 (35–83) | 59 (17–101) | 0.95 |
Data are represented as mean (SD), median (IQR) or n (%), as appropriate. Baseline characteristics of patients with RA treated with adalimumab (40 mg subcutaneously every 2 weeks), in combination with a stable MTX dose for at least 16 weeks, are described. Patients were compared, based on clinical response—according to the EULAR response criteria—at 16 weeks resulting in good/moderate responders (g/m) and non-responders (non), with a χ2 test, unpaired Student t test or Mann–Whitney U test, as appropriate. Presence of erosive joint disease was determined by x-ray. Presence of immunoglobulin M-RF was defined as serum levels ≥12.5 IU/ml and presence of ACPA was defined as serum levels ≥25 IU/ml.
ACPA, anticitrullinated peptide antibody; BMI, body mass index; CRP, C reactive protein; DAS28, disease activity score evaluated in 28 joints; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; GC, glucocorticoid; MTX, methotrexate; RF, IgM rheumatoid factor.